PASITHEA THERAPEUTICS CORP. Research and Development Expense
PASITHEA THERAPEUTICS CORP. (KTTA) reported Research and Development Expense of $3.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- PASITHEA THERAPEUTICS CORP. research and development expense for the quarter ending 2026-06-30 was $3.69M, a 71.53% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. research and development expense for the quarter ending 2026-03-31 was $2.94M, a 70.09% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. research and development expense for the quarter ending 2025-12-31 was $2.74M, a 81.77% increase year-over-year.
- PASITHEA THERAPEUTICS CORP. research and development expense for the quarter ending 2025-09-30 was $1.36M, a 14.14% decline year-over-year.
- PASITHEA THERAPEUTICS CORP. research and development expense for fiscal 2025 was $7.98M, a 10.87% increase from fiscal 2024.
- PASITHEA THERAPEUTICS CORP. research and development expense for fiscal 2024 was $7.20M, a 11.14% decline from fiscal 2023.
- PASITHEA THERAPEUTICS CORP. research and development expense for fiscal 2023 was $8.10M, a 203.92% increase from fiscal 2022.
- PASITHEA THERAPEUTICS CORP. research and development expense for fiscal 2022 was $2.67M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $3.69M 10-Q · filed 2026-08-14 | $6.63M 10-Q · filed 2026-08-14 | $9.37M derived: sum of 3 quarters · filed 2026-08-14 | $10.73M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-15 | $5.69M derived: sum of 2 quarters · filed 2026-05-15 | $7.04M derived: sum of 3 quarters · filed 2026-05-15 | $9.19M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $2.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.10M derived: sum of 2 quarters · filed 2026-03-30 | $6.25M derived: sum of 3 quarters · filed 2026-08-14 | $7.98M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $1.36M 10-Q · filed 2025-11-13 | $3.51M derived: sum of 2 quarters · filed 2026-08-14 | $5.24M 10-Q · filed 2025-11-13 | $6.75M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $2.15M 10-Q · filed 2026-08-14 | $3.88M 10-Q · filed 2026-08-14 | $5.39M derived: sum of 3 quarters · filed 2026-08-14 | $6.97M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $1.73M 10-Q · filed 2026-05-15 | $3.24M derived: sum of 2 quarters · filed 2026-05-15 | $4.82M derived: sum of 3 quarters · filed 2026-05-15 | $7.18M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $1.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.09M derived: sum of 2 quarters · filed 2026-03-30 | $5.45M derived: sum of 3 quarters · filed 2026-03-30 | $7.20M 10-K · filed 2026-03-30 | |
| 2024-09-30 | $1.58M 10-Q · filed 2025-11-13 | $3.94M derived: sum of 2 quarters · filed 2025-11-13 | $5.69M 10-Q · filed 2025-11-13 | $9.04M derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $2.36M 10-Q · filed 2025-08-14 | $4.11M 10-Q · filed 2025-08-14 | $7.46M derived: sum of 3 quarters · filed 2025-08-14 | $9.08M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $1.75M 10-Q · filed 2025-05-15 | $5.10M derived: sum of 2 quarters · filed 2025-05-15 | $6.73M derived: sum of 3 quarters · filed 2025-05-15 | $8.75M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $3.35M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $4.98M derived: sum of 2 quarters · filed 2025-03-24 | $7.00M derived: sum of 3 quarters · filed 2025-03-24 | $8.10M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $1.62M 10-Q · filed 2024-11-13 | $3.65M derived: sum of 2 quarters · filed 2024-11-13 | $4.75M 10-Q · filed 2024-11-13 | $6.14M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $2.03M 10-Q · filed 2024-08-13 | $3.12M 10-Q · filed 2024-08-13 | $4.51M derived: sum of 3 quarters · filed 2024-08-13 | $5.79M derived: sum of 4 quarters · filed 2024-08-13 | |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-14 | $2.48M derived: sum of 2 quarters · filed 2024-05-14 | $3.76M derived: sum of 3 quarters · filed 2024-05-14 | ||
| 2022-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $2.67M derived: sum of 2 quarters · filed 2024-03-29 | $2.67M 10-K · filed 2024-03-29 | ||
| 2022-09-30 | $1.28M 10-Q · filed 2023-11-13 | $1.16M 10-Q · filed 2022-11-14 | $1.28M 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Rocket One Inc. (RKTO) | United States | $0.019B |